These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 38360515)

  • 1. T2-FLAIR mismatch sign and machine learning-based multiparametric MRI radiomics in predicting IDH mutant 1p/19q non-co-deleted diffuse lower-grade gliomas.
    Tang WT; Su CQ; Lin J; Xia ZW; Lu SS; Hong XN
    Clin Radiol; 2024 May; 79(5):e750-e758. PubMed ID: 38360515
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advanced imaging parameters improve the prediction of diffuse lower-grade gliomas subtype, IDH mutant with no 1p19q codeletion: added value to the T2/FLAIR mismatch sign.
    Lee MK; Park JE; Jo Y; Park SY; Kim SJ; Kim HS
    Eur Radiol; 2020 Feb; 30(2):844-854. PubMed ID: 31446467
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The T2-FLAIR-mismatch sign as an imaging biomarker for IDH and 1p/19q status in diffuse low-grade gliomas: a systematic review with a Bayesian approach to evaluation of diagnostic test performance.
    Goyal A; Yolcu YU; Goyal A; Kerezoudis P; Brown DA; Graffeo CS; Goncalves S; Burns TC; Parney IF
    Neurosurg Focus; 2019 Dec; 47(6):E13. PubMed ID: 31786548
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diffusion- and perfusion-weighted MRI radiomics model may predict isocitrate dehydrogenase (IDH) mutation and tumor aggressiveness in diffuse lower grade glioma.
    Kim M; Jung SY; Park JE; Jo Y; Park SY; Nam SJ; Kim JH; Kim HS
    Eur Radiol; 2020 Apr; 30(4):2142-2151. PubMed ID: 31828414
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MRI Scoring Systems for Predicting Isocitrate Dehydrogenase Mutation and Chromosome 1p/19q Codeletion in Adult-type Diffuse Glioma Lacking Contrast Enhancement.
    Kang KM; Song J; Choi Y; Park C; Park JE; Kim HS; Park SH; Park CK; Choi SH
    Radiology; 2024 May; 311(2):e233120. PubMed ID: 38713025
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predicting 1p/19q codeletion status using diffusion-, susceptibility-, perfusion-weighted, and conventional MRI in IDH-mutant lower-grade gliomas.
    Yang X; Lin Y; Xing Z; She D; Su Y; Cao D
    Acta Radiol; 2021 Dec; 62(12):1657-1665. PubMed ID: 33222488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radiogenomic association between the T2-FLAIR mismatch sign and IDH mutation status in adult patients with lower-grade gliomas: an updated systematic review and meta-analysis.
    Han Z; Chen Q; Zhang L; Mo X; You J; Chen L; Fang J; Wang F; Jin Z; Zhang S; Zhang B
    Eur Radiol; 2022 Aug; 32(8):5339-5352. PubMed ID: 35169897
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiparametric MRI and T2/FLAIR mismatch complements the World Health Organization 2021 classification for the diagnosis of IDH-mutant 1p/19q non-co-deleted/ATRX-mutant astrocytoma.
    Sawlani V; Jen JP; Patel M; Jain M; Haq H; Ughratdar I; Wykes V; Nagaraju S; Watts C; Pohl U
    Clin Radiol; 2024 Mar; 79(3):197-204. PubMed ID: 38101998
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Diagnostic Value of Conventional MRI and CT Features in the Identification of the IDH1-Mutant and 1p/19q Co-Deletion in WHO Grade II Gliomas.
    Zhao K; Sun G; Wang Q; Xue Z; Liu G; Xia Y; Yao A; Zhao Y; You N; Yang C; Xu B
    Acad Radiol; 2021 Jul; 28(7):e189-e198. PubMed ID: 32359929
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The T2-FLAIR mismatch sign as a predictor of IDH-mutant, 1p/19q-noncodeleted lower-grade gliomas: a systematic review and diagnostic meta-analysis.
    Park SI; Suh CH; Guenette JP; Huang RY; Kim HS
    Eur Radiol; 2021 Jul; 31(7):5289-5299. PubMed ID: 33409784
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of partial T2-FLAIR mismatch sign and isocitrate dehydrogenase mutation in WHO grade 4 gliomas: results from the ReSPOND consortium.
    Lee MD; Patel SH; Mohan S; Akbari H; Bakas S; Nasrallah MP; Calabrese E; Rudie J; Villanueva-Meyer J; LaMontagne P; Marcus DS; Colen RR; Balana C; Choi YS; Badve C; Barnholtz-Sloan JS; Sloan AE; Booth TC; Palmer JD; Dicker AP; Flanders AE; Shi W; Griffith B; Poisson LM; Chakravarti A; Mahajan A; Chang S; Orringer D; Davatzikos C; Jain R;
    Neuroradiology; 2023 Sep; 65(9):1343-1352. PubMed ID: 37468750
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combining methionine-PET and MRI fluid-attenuated inversion-recovery mismatch to determine glioma molecular subtype.
    Ohmura K; Kumagai N; Kumagai M; Ikegame Y; Shinoda J; Yano H; Muragaki Y; Iwama T
    J Neuroimaging; 2023; 33(4):652-660. PubMed ID: 37158779
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantifying T2-FLAIR Mismatch Using Geographically Weighted Regression and Predicting Molecular Status in Lower-Grade Gliomas.
    Mohammed S; Ravikumar V; Warner E; Patel SH; Bakas S; Rao A; Jain R
    AJNR Am J Neuroradiol; 2022 Jan; 43(1):33-39. PubMed ID: 34764084
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The T2-FLAIR mismatch sign as an imaging marker for non-enhancing IDH-mutant, 1p/19q-intact lower-grade glioma: a validation study.
    Broen MPG; Smits M; Wijnenga MMJ; Dubbink HJ; Anten MHME; Schijns OEMG; Beckervordersandforth J; Postma AA; van den Bent MJ
    Neuro Oncol; 2018 Sep; 20(10):1393-1399. PubMed ID: 29590424
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radiographic assessment of contrast enhancement and T2/FLAIR mismatch sign in lower grade gliomas: correlation with molecular groups.
    Juratli TA; Tummala SS; Riedl A; Daubner D; Hennig S; Penson T; Zolal A; Thiede C; Schackert G; Krex D; Miller JJ; Cahill DP
    J Neurooncol; 2019 Jan; 141(2):327-335. PubMed ID: 30536195
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of diagnostic performance of radiologist- and AI-based assessments of T2-FLAIR mismatch sign and quantitative assessment using synthetic MRI in the differential diagnosis between astrocytoma, IDH-mutant and oligodendroglioma, IDH-mutant and 1p/19q-codeleted.
    Kikuchi K; Togao O; Yamashita K; Momosaka D; Kikuchi Y; Kuga D; Yuhei S; Fujioka Y; Narutomi F; Obara M; Yoshimoto K; Ishigami K
    Neuroradiology; 2024 Mar; 66(3):333-341. PubMed ID: 38224343
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantification of T2-FLAIR Mismatch in Nonenhancing Diffuse Gliomas Using Digital Subtraction.
    Cho NS; Sanvito F; Le VL; Oshima S; Teraishi A; Yao J; Telesca D; Raymond C; Pope WB; Nghiemphu PL; Lai A; Cloughesy TF; Salamon N; Ellingson BM
    AJNR Am J Neuroradiol; 2024 Feb; 45(2):188-197. PubMed ID: 38238098
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improving Noninvasive Classification of Molecular Subtypes of Adult Gliomas With Diffusion-Weighted MR Imaging: An Externally Validated Machine Learning Algorithm.
    Guo Y; Ma Z; Pei D; Duan W; Guo Y; Liu Z; Guan F; Wang Z; Xing A; Guo Z; Luo L; Wang W; Yu B; Zhou J; Ji Y; Yan D; Cheng J; Liu X; Yan J; Zhang Z
    J Magn Reson Imaging; 2023 Oct; 58(4):1234-1242. PubMed ID: 36727433
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MR textural analysis on T
    Rui W; Ren Y; Wang Y; Gao X; Xu X; Yao Z
    J Magn Reson Imaging; 2018 Jul; 48(1):74-83. PubMed ID: 29140606
    [TBL] [Abstract][Full Text] [Related]  

  • 20. T2/FLAIR-mismatch sign for noninvasive detection of IDH-mutant 1p/19q non-codeleted gliomas: validity and pathophysiology.
    Foltyn M; Nieto Taborda KN; Neuberger U; Brugnara G; Reinhardt A; Stichel D; Heiland S; Herold-Mende C; Unterberg A; Debus J; von Deimling A; Wick W; Bendszus M; Kickingereder P
    Neurooncol Adv; 2020; 2(1):vdaa004. PubMed ID: 32642675
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.